These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 22110488)
1. The role of uridine adenosine tetraphosphate in the vascular system. Matsumoto T; Tostes RC; Webb RC Adv Pharmacol Sci; 2011; 2011():435132. PubMed ID: 22110488 [TBL] [Abstract][Full Text] [Related]
2. Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes. Matsumoto T; Goulopoulou S; Taguchi K; Tostes RC; Kobayashi T Br J Pharmacol; 2015 Aug; 172(16):3980-4001. PubMed ID: 26031319 [TBL] [Abstract][Full Text] [Related]
3. Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update. Zhou Z; Matsumoto T; Jankowski V; Pernow J; Mustafa SJ; Duncker DJ; Merkus D Pharmacol Res; 2019 Mar; 141():32-45. PubMed ID: 30553823 [TBL] [Abstract][Full Text] [Related]
4. Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats. Matsumoto T; Tostes RC; Webb RC Pharmacol Res; 2012 Jan; 65(1):81-90. PubMed ID: 21933714 [TBL] [Abstract][Full Text] [Related]
5. The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation. Schuchardt M; Prüfer J; Prüfer N; Wiedon A; Huang T; Chebli M; Jankowski V; Jankowski J; Schäfer-Korting M; Zidek W; van der Giet M; Tölle M J Mol Med (Berl); 2011 Aug; 89(8):799-810. PubMed ID: 21487675 [TBL] [Abstract][Full Text] [Related]
6. Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Jankowski V; Tölle M; Vanholder R; Schönfelder G; van der Giet M; Henning L; Schlüter H; Paul M; Zidek W; Jankowski J Nat Med; 2005 Feb; 11(2):223-7. PubMed ID: 15665829 [TBL] [Abstract][Full Text] [Related]
7. Uridine adenosine tetraphosphate-induced contraction is increased in renal but not pulmonary arteries from DOCA-salt hypertensive rats. Matsumoto T; Tostes RC; Webb RC Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H409-17. PubMed ID: 21551273 [TBL] [Abstract][Full Text] [Related]
8. Uridine adenosine tetraphosphate induces contraction of airway smooth muscle. Gui Y; Wang Z; Sun X; Walsh MP; Li JJ; Gao J; Zheng XL Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L789-94. PubMed ID: 21840961 [TBL] [Abstract][Full Text] [Related]
9. Purinergic transmission in blood vessels. Ralevic V; Dunn WR Auton Neurosci; 2015 Sep; 191():48-66. PubMed ID: 26004513 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. Tölle M; Schuchardt M; Wiedon A; Huang T; Klöckel L; Jankowski J; Jankowski V; Zidek W; van der Giet M Br J Pharmacol; 2010 Oct; 161(3):530-40. PubMed ID: 20880394 [TBL] [Abstract][Full Text] [Related]
12. Contribution of Rho-kinase and Adenosine Monophosphate-Activated Protein Kinase Signaling Pathways to Endothelium-Derived Contracting Factors Responses. Balcilar C; Özakça I; Altan VM Turk J Pharm Sci; 2017 Aug; 14(2):207-212. PubMed ID: 32454615 [TBL] [Abstract][Full Text] [Related]
13. Control of vascular tone by purines and pyrimidines. Burnstock G Br J Pharmacol; 2010 Oct; 161(3):527-9. PubMed ID: 20880393 [TBL] [Abstract][Full Text] [Related]
14. Uridine adenosine tetraphosphate is a novel vasodilator in the coronary microcirculation which acts through purinergic P1 but not P2 receptors. Zhou Z; Merkus D; Cheng C; Duckers HJ; Jan Danser AH; Duncker DJ Pharmacol Res; 2013 Jan; 67(1):10-7. PubMed ID: 23063485 [TBL] [Abstract][Full Text] [Related]
15. Endothelial dysfunction: a strategic target in the treatment of hypertension? Tang EH; Vanhoutte PM Pflugers Arch; 2010 May; 459(6):995-1004. PubMed ID: 20127126 [TBL] [Abstract][Full Text] [Related]